Q2 FY27 profit rises sharply; Ibuprofen review delayed by 12 weeks

Management guided margin improvementManagement guided margin pressureCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹612.30

prior close

₹608.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+3.2% vs market

Pharmaceuticals peers, median of 174sector+1.2%+2.4% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+2.9

15m

+4.3

30m

+4.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.4+3.2+1.2+2.4

Next day

+3.7+2.1+1.6+3.1+0.6

+6.6+2.2+4.4+4.7+1.9

+6.5+2.9+3.6+4.7+1.8

+3.4+0.3+3.1+3.2+0.1

+3.7+1.8+2.0+3.2+0.5

+5.7+4.2+1.5+4.9+0.9

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 33% to INR418 crore. EBITDA doubled to INR77 crore, lifting margin to 18.4%, while profit reached INR28.5 crore versus a INR10 crore loss. Base revenue grew 37%, and Ibuprofen rose 21% while nearing break-even. Net debt fell to about INR500 crore from INR614 crore. Management expects input cost pressure for one to two quarters, but sees margin gains from volumes and cost control. Ibuprofen review needs 12 more weeks.

Likely market impact

Strong earnings and lower debt are positive for shareholders, but input cost pressure and Ibuprofen review uncertainty may cap near-term stock gains.